Evidence map›Paper›PMID 36353495›Full record

ArticleFrontiers in pharmacology2022

Integrated network pharmacology and metabolomics to reveal the mechanism of QiShenYiQi Dripping Pills (T101) against cardiac structural and functional abnormalities.

Jun Zhang, Zunyuan Yang, Xue Jia, Xinxin Li, Xiangyang Wang, Hua Rong, Yinan Liang, Wen Zeng, Wei Jia, Xiaohui Ma

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jun ZhangThe State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd, Tianjin, China.
Zunyuan YangPriMed Non-Human Primate Research Center of Sichuan PriMed Shines Bio-Tech Co., Ltd., Ya'an, Sichuan, China.
Xue JiaInstitute of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing, China.
Xinxin LiThe State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd, Tianjin, China.
Xiangyang WangThe State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd, Tianjin, China.
Hua RongThe State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd, Tianjin, China.
Yinan LiangPriMed Non-Human Primate Research Center of Sichuan PriMed Shines Bio-Tech Co., Ltd., Ya'an, Sichuan, China.
Wen ZengPriMed Non-Human Primate Research Center of Sichuan PriMed Shines Bio-Tech Co., Ltd., Ya'an, Sichuan, China.
Wei JiaCenter for Translational Medicine and Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Xiaohui MaThe State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd, Tianjin, China.
Tasly Holding Group (China) · CNChina Pharmaceutical University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

heart failuremetabolomicspharmacology networkQSYQ (T101)SHR

Identifiers

PMID36353495
PMCPMC9638142
OpenAlexW4307271544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.